Replies to post #16266 on Cdex, Inc. (fka CDEX)

[Crow3]

As I and others have been saying all along, Valimed is in a small market as presently configured. It will never provide really significant revenue..even if it has "saved a life" or two. Sob stories are not a viable basis for sales.

Likewise, the Meth gun will be a niche market, if ever deployed.

Here the company sits, no money, no products that will ever generate a whole lot of revenue, and save the shareholders from loss.

The INONITs can make a dime or a dollar..lots of them, in fact. The shareholders are restricted to selling shares back and forth to each other, and the occaisional new sucker.

[high C]

Crow/millie; what the he44 difference does it make if he sold 10 or 25 or 30 ValiMeds as long as he reports the revenue as he projected: app $ 950,000 in next filing and meets his projected $3,000,000, in a couple of years.

It makes sense Baxa has a selling price and a purchase price from Cdex. if that is broadcast or can be compiled from numbers sold vs plus cuvettes etc,it would theoretically be a locked in price.

Keeping a running tab on units and sales Cdex to Baxa to hospitals,puts a crimp in most salesmens opportunities. Why couldn't Baxa have different prices as per quantity purchases.

If Cdex/Baxa approaches Canadian or overseas hospitals, or distributors,it would be hard to deviate from what is known about earlier sales.

Why face that problem ,just so we shareholders can say "whoopie ,we are getting such and such for ValiMed and we sold ???".

IMO the revenue is what counts,not short term reassurances that we are still in business.

The price is not going to raise on BS reports,we shareholders should have had that knocked into our heads, by your old standby buddies,that you keep referring to. LOL

I believe they are trying to build a legitimate company ,no matter how tough it may be.

Of course this is a wasted post, since common sense does not fly here.LOL